AbbVie Inc. (ABBV) Stock Analysis
A live, multi-source view of AbbVie Inc. (ABBV): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.
Sector: Healthcare · Industry: Drug Manufacturers - General · United States · 57,000 employees · abbvie.com
Key statistics · as of 2026-09-05
As of 2026-09-05, AbbVie Inc. (ABBV) had a market capitalization of $453.19B, a trailing P/E of 73.5 (forward 15.8), a dividend yield of 2.66% and a beta of 0.28; the shares traded in a 52-week range of $190.75 – $267.47 (22.4% over the year).
- Market cap
- $453.19B
- Enterprise value
- $517.56B
- Trailing P/E
- 73.5
- Forward P/E
- 15.8
- PEG ratio
- 0.37
- EPS (trailing)
- $3.49
- EPS (forward)
- $16.28
- Dividend yield
- 2.66%
- Payout ratio
- 190.4%
- Ex-dividend date
- 2026-07-15
- 52-week range
- $190.75 – $267.47
- 52-week change
- 22.4%
- Beta
- 0.28
- Average volume
- 6.4M
- Shares outstanding
- 1.77B
- Short % of float
- 1.15%
- Profit margin
- 9.8%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, AbbVie Inc. (ABBV) last closed at $255.00 (the last completed close before that scan).
Technicals at the scan: RSI 50 (neutral territory), price -1.1% versus its 20-day average, 20-day versus 50-day average spread +1.4%, MACD histogram -1.30.
Sentiment inputs: 88% of recent Finnhub-scored headlines read bullish; StockTwits 80% bullish; analyst consensus score 75/100.
Next scheduled company event: in 48 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 1 buy and 0 sells of ABBV; corporate insiders filed 0 buys and 1 sell (2 distinct filers, latest disclosure 2026-08-18). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Nicholas Donoghoe (0B/1S), Alan Armstrong (1B/0S). Who is trading what
RapidTradeView pick record
ABBV has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls AbbVie Inc. (ABBV) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell ABBV.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.